The mean increase in visual acuity now stands at 23 letters, well above the level deemed clinically meaningful by the FDA.

The action follows the failure of the anti-B7RP1 antibody in a midphase Sjöogren’s syndrome trial.

Scientists characterized the structures of melatonin receptors, which they say could enable design of better drugs to treat sleep disorders.

In this week's EuroBiotech Report, Genentech backs U.K. startup accelerator, GSK punts failed heart drug and more. 

Gilead’s NASH candidate selonsertib did worse than placebo at reducing scarring in NASH patients with stage 3 fibrosis.

In our EuroBiotech roundup this week, Cinclus and Cytura raise cash, Mereo completes merger and Marinomed posts phase 3 data. 

J&J and Boston University scientists identified genomic alterations in the immune system that could lead to early lung cancer development.

The action sees Daiichi pay Zymeworks $3.5 million to license an asset based on its bispecific antibody platform.

The Bausch Health subsidiary plans to trial the ex-Biogen S1P receptor functional antagonist in ulcerative colitis.